ACRO Issues Statement on 2026 Physician Fee Schedule Final Rule

Press Release
Article

Due to certain errors in the 2026 PFS Final Rule pre-publication, ACRO has issued a statement while awaiting the publication of the 2026 HOPPS Final Rule.

ACRO advocated for a correction in the 2026 HOPPS Final Rule and, while the HOPPS Final Rule has not been published, it appears by inference that a correction did occur based on the rates in the 2026 PFS Final Rule.

ACRO advocated for a correction in the 2026 HOPPS Final Rule and, while the HOPPS Final Rule has not been published, it appears by inference that a correction did occur based on the rates in the 2026 PFS Final Rule.

The 2026 Physician Fee Schedule (PFS) Final Rule was published in the Federal Register on November 5. Due to errors contained in certain addenda in the 2026 PFS Final Rule pre-publication on October 31, the American College of Radiation Oncology has issued a statement while awaiting the publication of the 2026 Hospital Outpatient PPS (HOPPS) Final Rule.

ACRO advocated for a correction in the 2026 HOPPS Final Rule and, while the HOPPS Final Rule has not been published, it appears by inference that a correction did occur based on the rates in the 2026 PFS Final Rule. ACRO estimates that this correction results in an smaller cut in 2026 rates for radiation treatment delivery services in comparison to 2025 from -10% in the 2026 PFS Proposed Rule to -3.8% in the 2026 PFS Final Rule. Separately, the Indirect Practice Expense (IPE) policy in the 2026 PFS Final Rule increases rates for non-treatment delivery codes by 5.2%, which offsets these reductions in the treatment delivery codes.

Click here to read the statement released by ACRO.

Recent Videos
Although 1 of 21 patients with liver-dominant NETs died due to RILD in the phase 1 study, no RILD-induced deaths were observed in the phase 2 trial.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
A new partnership agreement involving AI use may help spread radiotherapeutic standards from academic centers to more patients in community-based practices.
Recent findings presented at ASTRO 2025 suggest an “exciting opportunity” to expand the role of radiation oncology in different non-malignant indications.
The 3 most likely directions of radiotherapy advancements come from new technology, combinations with immunotherapy, and the incorporation of particle therapy.
Distance and training represent 2 major obstacles to making radiotherapy available to more patients with cancer across the world.
Louis Potters, MD, FASTRO, FABS, FACR, describes how evidence-based radiation protocols may integrate with novel artificial intelligence software.
Related Content